AI Shifts Into the Next (Generative) Gear in Healthcare
Summary
Artificial intelligence (AI) has been transforming health and medicine for several decades, whether through diagnostics, personalized medicine, data analytics or other innovations. The advent of generative AI is now reshaping drug discovery, diagnostics, clinical decisions and delivery of care. Traditional healthcare companies — whether healthcare providers, payers, technology partners or pharmaceutical companies — recognize generative AI’s potential. That potential can manifest in the form of faster drug discovery, more accurate diagnostic tools, improved clinical care and patient services, and so on. Each stakeholder is seeking ways to use the technology to their advantage. Medical professionals, patients and regulators are reacting to this new reality, pondering its implications — both promising and troubling — as well as yet-unanswered ethical questions. Health tech and Big Tech join forces on generative AI solutions. Today, traditional health IT and health-tech companies are partnering with tech giants such as Google, Amazon, Microsoft and Meta to bring their generative AI solutions to life. Leading health IT provider Epic’s partnership with Microsoft to integrate generative AI into its electronic health record (EHR) software is a notable example. The takeaway for both industry stakeholders and generative AI users is to watch investor actions. Sustained investor interest will drive the development of stronger, more effective use cases and lead to the emergence of numerous industry- specific generative AI applications in the years ahead. This trend mirrors the introduction of new technologies in previous decades. Startups set the stage for generative AI in healthcare. The generative AI market for healthcare is valued at more than $1 billion as of 2022, and it is projected to swell to almost $22 billion by 2032. Technology giants along with venture capitalists and private equity investors will play a significant role in that market as investors, partners and innovators. These investments stand to benefit tech startups like Abridge, which is working to integrate its generative AI medical note-taking tool with Epic, a move that promises to streamline clinical workflows. Similarly, startup company Basys.ai secured $2.4 million in seed funding to advance its prior authorization tool, which leverages generative AI and deep learning to expedite the insurance preapproval process for medical procedures. Doctors and patients must have a say in shaping generative AI’s role in clinical settings. For every claim of generative AI’s promise made by technology developers, there is often a fear of the unknown held by nearly everyone else, from medical professionals and patients to government officials. Medical professionals can play a crucial role in demystifying that unknown, especially for their patients. As the experts in care, they have earned patients’ trust through decades of experience and will be responsible for using generative AI in the clinical setting. Patients also must be part of the equation because, after all, it is their health that is at stake. Their fears, comfort levels, trust and consent are factors in determining whether and to what extent generative AI should be involved in their treatment.The post AI Shifts Into the Next (Generative) Gear in Healthcare first appeared on PYMNTS.com.
The Clearing House’s RTP network and The Fed's FedNow network are prepared to tackle interoperability eventually — but for now, its value remains minimal.
FedNow, RTP interoperability is inevitable — down the line
Digital Currencies
Summary
The Clearing House’s RTP network and The Fed's FedNow network are prepared to tackle interoperability eventually — but for now, its value remains minimal.
The post Solana Struggles Amid Intense Bearish Pressure at Resistance Lines: What’s Next for SOL Price appeared first on Coinpedia Fintech News Solana pri…
Solana Struggles Amid Intense Bearish Pressure at Resistance Lines: What’s Next for SOL Price
Blockchain · Digital Currencies
Summary
The post Solana Struggles Amid Intense Bearish Pressure at Resistance Lines: What’s Next for SOL Price appeared first on Coinpedia Fintech News Solana price has been declining steeply following the SEC’s approval of spot Ethereum ETFs. For example, the SOL/ETH pair, which is closely monitored, has dropped by 16.8% since May 17 following the U.S. Securities and Exchange Commission’s (SEC) request for Ether ETF applicants to revise their 19b-4 filings. Additionally, there’s a decline in activity in the SOL ecosystem, suggesting further bearish pressure on the edge. Analysts Expect SOL ETF By 2025 Solana might be losing its momentum to Ethereum following SEC’s approval of spot ETH ETF. However, analysts believe that Solana is not far from having its own ETF. Geoffrey Kendrick, an analyst at Standard Chartered, predicts that SOL and XRP ETFs could receive approval by 2025. Kendrick suggests that the recent approval of the ETH ETF implies that Ether and altcoins may not be classified as securities. Analysts from The Birb Nest have observed that discussions around a Solana ETF are surging on crypto Twitter and in media circles, indicating that it’s likely to happen. The total value locked (TVL) within the Solana ecosystem experienced a notable decline in May. As of May 23, there were 27.48 million SOL locked, down from the monthly peak of 29.4 million SOL. This decline in Solana’s TVL was particularly sharp after May 20, following reports on the potential approval of spot Ether ETFs. On that date, the TVL was recorded at 28.3 million SOL, suggesting that the news about the Ether ETFs might have triggered the withdrawals from the Solana ecosystem. Since the Ethereum ETF approval on May 20, Solana node validators started rapidly withdrawing funds. Initially holding 368.8 million SOL in staking contracts, they withdrew 3.5 million SOL by May 24, reducing the active staking to 365.3 million SOL. Also read: Analyzing the Effect of Approval of Ethereum ETF on Solana: Market Trends and Price Prediction With Solana’s current price at $167, these unstaked SOL are valued at approximately $580 million. Such significant withdrawals from a Proof-of-Stake (PoS) network generally lead to short-term price declines. What’s Next For SOL Price? Solana price failed to break above $190 as sellers strongly defended a surge above that level, resulting in a steep decline below immediate Fib channels. SOL price dropped below its EMA trend lines too; however, buyers defended further drops below $160. As of writing, SOL price trades at $166, declining over 4% in the last 24 hours. SOL price is struggling to surpass the EMA20 trend line, indicating continued bearish pressure at higher levels. The declining EMA trend lines and the RSI level heading toward the oversold region suggest a rising dominance in bearish positions. Should buyers push past the descending resistance line, the SOL/USDT pair might aim to retest the significant resistance at $192. A break above this level might send the SOL price toward $210.
The Securities and Exchange Commission (SEC) is poised to green-light Ethereum (Ether) ETFs after years of pushback. As of this writing, it was not clear …
Digital Currencies · Banking Infrastructure · Blockchain
Summary
The Securities and Exchange Commission (SEC) is poised to green-light Ethereum (Ether) ETFs after years of pushback. As of this writing, it was not clear as
Services: Binance, YouHodler, Digital Asset, Lolli, Ethereum, Coinbase, Bitcoin